Apellis Pharmaceuticals, Inc. (APLS) Q2 2022 Earnings Results

Apellis Pharmaceuticals Misses on EPS — Stock Down 1.58%

This earnings report indicates that Apellis Pharmaceuticals is still facing challenges, as reflected in their EPS miss. The stock reacted negatively, dropping 1.58% in response to the results. Investors may be concerned about the lack of revenue details and forward guidance, which adds uncertainty to the company's outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.46	N/A	-2.10%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding future developments. They emphasized their commitment to advancing their pipeline despite current challenges.

Management highlighted ongoing efforts in product development.

They acknowledged challenges but expressed confidence in long-term strategy.

Apellis Pharmaceuticals Misses on EPS — Stock Down 1.58%

Key numbers

Management commentary

Apellis Pharmaceuticals, Inc.

More earnings this week

Apellis Pharmaceuticals Misses on EPS — Stock Down 1.58%

Key numbers

Management commentary